Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients

FDA Clears Initiation of Efficacy Trial for C3 Glomerulopathy (C3G) CLEVELAND, Aug. 15, 2022 -- (Healthcare Sales & Marketing Network) -- NovelMed Therapeutics is a clinical-stage biopharmaceutical company focused on the development of targeted therapi... Biopharmaceuticals, FDA NovelMed Therapeutics, Anti-Bb Antibody, Glomerulopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news